OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) saw a significant increase in short interest in January. As of January 15th, there was short interest totaling 159,454 shares, an increase of 212.9% from the December 31st total of 50,958 shares. Approximately 0.7% of the company’s stock are sold short. Based on an average trading volume of 286,690 shares, the short-interest ratio is currently 0.6 days. Based on an average trading volume of 286,690 shares, the short-interest ratio is currently 0.6 days. Approximately 0.7% of the company’s stock are sold short.

OKYO Pharma Stock Up 1.8%

Shares of NASDAQ OKYO traded up $0.04 during trading on Wednesday, reaching $2.17. 983,366 shares of the stock traded hands, compared to its average volume of 338,922. The company has a 50-day moving average of $2.12 and a 200-day moving average of $2.33. OKYO Pharma has a 52-week low of $0.90 and a 52-week high of $3.35.

Analysts Set New Price Targets

A number of equities analysts have issued reports on OKYO shares. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research note on Thursday, January 22nd. B. Riley started coverage on shares of OKYO Pharma in a report on Monday, December 8th. They set a “buy” rating and a $5.00 price target on the stock. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OKYO Pharma stock. Wealth Enhancement Advisory Services LLC acquired a new stake in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $28,000. Institutional investors and hedge funds own 2.97% of the company’s stock.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.